Exium Asset Management Acquires 278,241 Convertible Bonds of ADBIOTECH, Stake Drops to 4.20% Due to Share Increase
Exium Asset Management, a major shareholder of ADBIOTECH, acquired 278,241 convertible bonds in an off-market transaction, increasing its CB holdings to 1,143,160. The purchase price was 1,833 KRW per bond, approximately 17% below the current stock price of 2,215 KRW.
The acquisition is for simple investment purposes. The low conversion price of the CBs implies potential dilution upon conversion. However, the total outstanding shares increased from 16,360,379 to 26,950,299, causing the overall stake to decrease from 5.29% to 4.20%.
The filer, Exium Asset Management, is a financial investment firm with 15.29 billion KRW in assets under management, and no special relationships were reported. There is no lock-up period for the acquired bonds.
[AI Summary]Exium Asset Management's additional CB purchase in ADBIOTECH appears aimed at expanding its stake at a discount, but the simple investment purpose and lack of lock-up allow for potential short-term profit-taking. While the stake percentage fell due to share increase, the convertible bonds' dilutive effect may pressure the stock price.